Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@try2buylow
Not too keen on the use of the term 'road map' as it implies a clear start point and destination.
Give the amount of uncertainty, its almost impossible and can only lead to false reassurances, higher than realistic expectations and ultimately disappointments and investor mistrust.
IMO, a clear strategy based on a series of achievable targets or waypoints is much preferred.
I agree the broker information is the best available which in itself seems mad to me.
Information available to the market sets the SP at roughly half the broker estimate. That isn't a very effective outcome in assessing an investment. The brokers might be over or under the real potential now & that over/under is bound to change over time without visibility in the market. Most people run a mile from investments on that basis which is why some businesses go to great lengths to set expectations. So for example, if they know their single most significant contract will go into a period of negotiation under confidentiality they might advance their reporting of their financial year end or up their explanation of plans, developments & prospects.
This lot don't have a complicated finance system so advancing their YE announcement would probably be less work than hanging around until end of April as they plan. It would also be easier to announce what a strategic plan is if they were that way inclined but perhaps the finance function is still not yet in a position to lead on this gap.
I am saying this an investor with finance background in quoted companies from AIM to FTSE100. Presenting enough information for investment community to be able to understand metrics is a choice. It is not that hard & can be done guarding confidentiality. It is perhaps less methodical and disciplined than management behind NCYT projects but is usually led by finance.
We investors should not really have to rely on the razor sharp wits of our BB community to glean snippets of what this company has been achieving, we ought to have a road map of its priorities by business activities setting areas that are confidential off limits & as much information as can be announced on non confidential stuff. Simple information coming from the company would help hold the SP from drifting (& presumably ever lower before the next big event +/-).
They don't accept science that is 50% effective so why do they allow such ineffectiveness in investor relations? "because they are scientists", or "because they are massively busy are reasons" with limited shelf lives and adverse consequences that might easily be avoided IMO.
Airline boy , think quite clearly we have been told that It us being used, to me that is 100 % positive .
Think your reading WAAAAYYYY tooooo much into this.
quite right
simple by the way why did you write what you did - I thought you are invested so why would you say the opposite of what is really happening
So here are the facts... Reading some saying testing is falling off a cliff edge - this seems to suggest its still high and pretty flat on the PCR front:
https://coronavirus.data.gov.uk/details/testing
I suspect it was a cunning ploy HKTrader and personally I think it will be great for the SP today. Everyone sat up last evening and fully digested the underlined information. Our kit is used extensively within the NHS AND worldwide. I think it was a pointer to all of us that the DHSC contract has either been extended OR renewed, maybe both! All good and all carefully played on their part. Masterful!
My best guess is to send in a draft version of the English RNS by mistake.
Only seen this: https://novacyt.com/2021/02/24/correction-research-and-development-update/
Difference didnt seem to make much impact in France with the SP and activity there... Anyone think it will do much for UK side. Pretty late announcement so not factored into yesterdays trading. How could they publish such a big piece of info inconsistently???
That was meant to say 'it's 2022 and beyond that is most important to investors'. Ncyt have proved they can generate huge returns during the pandemic, we now need to see how they are going to keep driving forward post-pandemic.
2021 looks very good, I expect revenues to exceed 2020 but it's 2022 and beyond that investors are most important. When the future plans for the company are unveiled sometime in Q2 that should be the stimulus that gets the share price moving.
@Naewise
I tend to agree with you
You would think by now that any Vaccine news is well and truly factored in. The UK could be swimming in different vaccines frankly but it doesn't change anything.
The harsh fact is that we will have to live with this virus, it is going to mutate and keep changing just like the flu virus each year. Hence vaccines will need to be constantly updated - this is where our whole gene sequencing data comes in.
Meanwhile, its a fact that by end of June, in a best case scenario in the UK with maximum vaccine take up there will still be something like 30-33% continuing exposure risk of the virus and that's just the UK and we are one of the best placed. USA and ROW in a far worse position now.
Hence we will need ongoing testing, NHS fully prepared so they know exactly what they are dealing with, whole gene sequencing to keep on top of new variants and surge lockdowns in places were a new variant breaks out.
Not great
Looking forward to Fridays whole genome sequencing event, that could give us some more information on the outlook.
I m still holding
Good points Porky9 and I tend to agree. H1 results are all important. I had hoped the late corrected RNS yesterday might give us a little boost today but this will probably be nullified by approval of the Johnson vaccine.
Whilst i genuinely believe H1 Results will likely exceed estimates due to current success, I'm not expecting anything further reported on revenues over the next few weeks unless something material changes the current outlook.
As such i'm going 100% off both broker forecasts namely:-
Numis Security
Revenues 317m EBITDA 201m CASH at Bank 279m Fair Value SP £ 13.65
S P Angel
Revenues 271m EBITDA 173m CASH at Bank 278m Fair Value £ 14.33
Numis to the year end were within 5%, they updated the forecast only yesterday hence i expect that forecast to remain VERY accurate. Under normal market conditions you would expect to see our SP significantly higher in relation its fundamental strength but clearly this is being ignored.
So with sentiment low due to vaccine success in the UK and rainbow chasing elsewhere it looks like we need something material to land to change retail sentiment / attract new investor interest to boost the SP namely:-
1. A substantial order (such as DHSC which is looking possible or something Stateside)
2. A partner / Major White label or license deal Agreed
3. An acquisition / Acquisition creating long term revenues
4. Some government deal to come out of whole genome sequencing
5. New product launch that can add revenues directly or under license (saliva tests / antibody tests possible)
6. A move to Nasdaq where the stock is opened up to a significantly bigger trading market audiance
Personally, i believe the next few weeks for Novacyt through to H1 results will paint its direction. If NONE of the above are forthcoming and the SP continues to drift on low sentiment then a takeover looks more likely.
Unless anyone has anything to add to this list this is how i currently see it??
Porks